Fresenius Medical Care and company founder Avera Health both took part in a round that will fund clinical trials of Alucent's vascular disease treatment.
US-based vascular disease treatment developer Alucent Biomedical has completed a $35m series B round featuring kidney dialysis provider Fresenius Medical Care and healthcare provider Avera Health.
The round was led by an unnamed strategic investor and Fresenius participated through corporate venture capital subsidiary Fresenius Medical Care Ventures.
Founded by Avera Health subsidiary Avera Research Institute, Alucent has created a treatment system that combines drugs and hardware to treat peripheral artery disease (PAD) in the body’s lower extremities.
The system, dubbed…
